Pfizer to cut jobs in r&d restructure
Pfizer is to "significantly reduce" r&d activities at some of its sites following the integration of Wyeth. The company will close six r&d sites and cut jobs in the US and the UK, reducing its global r&d square footage by 35%.
Pfizer is to "significantly reduce" r&d activities at some of its sites following the integration of Wyeth. The company will close six r&d sites and cut jobs in the US and the UK, reducing its global r&d square footage by 35%.
A number of functions will be moved from Collegeville, PA; Pearl River, NY; and St Louis to other locations, while operations in Princeton, NJ; Chazy, Rouses Point and Plattsburgh, NY; Sanford and Research Triangle Park, NC; and Gosport, Slough/Taplow, UK will be closed. In addition, Pfizer will consolidate its r&d functions in Connecticut, US.
"While these changes are expected to bolster productivity and reduce costs, they will result in staff reductions," said Pfizer.
The company will now conduct r&d at five main sites and nine specialised units around the world, compared with 20 r&d sites upon closing the acquisition of Wyeth.
The five main research sites will conduct activities in BioTherapeutics, PharmaTherapeutics and Vaccines, the company said. These sites are: Cambridge, MA; Groton, Conn; Pearl River, NY; La Jolla, California; and Sandwich, U.K. These research-oriented laboratories will be supplemented by specialised research capabilities, such as monoclonal antibody discovery in San Francisco, regenerative medicine work in Cambridge, UK, and r&d activities in Shanghai, China.
"This new structure puts Pfizer in the best position to conduct cutting-edge research within and beyond our own laboratories and to deliver a portfolio of high-impact medicines to patients," said Mikael Dolsten, president of BioTherapeutics r&d at Pfizer.